{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:07:49Z","timestamp":1790356069675,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03190-0","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:21:23Z","timestamp":1788686483000},"page":"2073-2074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia"],"prefix":"10.1007","volume":"31","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"3190_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on Aug 26, 2026"},{"key":"3190_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","volume":"393","author":"X Le","year":"2025","unstructured":"Le X, Kim TM, Loong HH et al (2025) Sevabertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med 393:1819\u20131832. https:\/\/doi.org\/10.1056\/NEJMoa2511065","journal-title":"N Engl J Med"},{"key":"3190_CR3","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1200\/JCO-25-01651","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand S, Van der Heijden MS, Jacob JM et al (2025) TAR-200 for Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J Clin Oncol 43:3578\u20133588. https:\/\/doi.org\/10.1200\/JCO-25-01651","journal-title":"J Clin Oncol"},{"key":"3190_CR4","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"3190_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1805131","journal-title":"N Engl J Med"},{"key":"3190_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMoa2502449","volume":"393","author":"D Rischin","year":"2025","unstructured":"Rischin D, Porceddu S, Day F et al (2025) Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med 393:774\u2013785. https:\/\/doi.org\/10.1056\/NEJMoa2502449","journal-title":"N Engl J Med"},{"key":"3190_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H et al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 406:2221\u20132234. https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5","journal-title":"Lancet"},{"key":"3190_CR8","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","volume":"12","author":"R Mesa","year":"2025","unstructured":"Mesa R, Gill H, Zhang L et al (2025) Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol 12:e862\u2013e875. https:\/\/doi.org\/10.1016\/S2352-3026(25)00264-9","journal-title":"Lancet Haematol"},{"key":"3190_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Revisions of PRECAUTIONS (FY2026). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0014.html Accessed on Aug 26, 2026"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03190-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:49:55Z","timestamp":1790354995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03190-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03190-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"6 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}